TY - JOUR ID - 133478 TI - Treatment of migraine headache with Migracorb, caffeine and ascorbic acid combination JO - Health Biotechnology and Biopharma (HBB) JA - HBB LA - en SN - Y1 - 2018 PY - 2018 VL - 2 IS - 3 SP - 36 EP - 47 KW - Migraine Headache KW - Vitamin C KW - Caffeine DO - 10.22034/HBB.2018.25 N2 - The migraine mechanism; the release of inflammatory neuropeptides, nuclear factor (NF-kB) and proinflammatory proteins leads to increase blood vessel permeability, tissue edema and pain sensitization. From 1989 to 2013 in a single blind randomized clinical trial conducted in Shiraz central hospital, 700 cases (460 females and 240 males) with the diagnosis of moderate to severe pain intensity migraine were enrolled. The cases (n=350) were put on vitamin C (ascorbic acid) 25 mg in a capsule mixed in a cup of tea (100 ml) containing about 20 mg caffeine (Migracorb), to drink three times per day with sugar. The controls (n=350) drank three times per day with sugar. 22 % of the female cases and 7.5 % of the male cases had abortive response to Migracorb from 10 min to 3 h. 53 % of the female cases and 39 % of the male cases were cured by taking Migracorb after 6 months. Only 0.5 % of the female control group cases were cured after 6 months.The combination of vitamin C as antioxidant and caffeine as anti-inflammation cured a significant number of patients with migraine headache. UR - https://www.healthbiotechpharm.org/article_133478.html L1 - https://www.healthbiotechpharm.org/article_133478_c7b7c4056927008b3a0b0740ef3ae344.pdf ER -